AtriCure (NSDQ:ATRC) registered for a securities offering worth $150 million that could bring in another $115 million for some of its stockholders in a secondary offering.
West Chester, Ohio-based AtriCure said its portion of the flotation could include common stock, preferred stock, debt securities, warrants or depositary shares and units. The company won’t get any proceeds from the secondary offering of nearly 5.6 million shares, according to a regulatory filing.
AtriCure said it plans to use the proceeds for general corporate purposes, including paying down debt.
In April, the FDA granted 510(k) clearance to a pair of AtriCure devices: the AtriClip Pro2 left atrial appendage exclusion system and the CryoForm cardiac cryoablation probe. The company is also running a 2,000-patient trial, designed to compare the economics of treating post-operative atrial fibrillation patients with AtriClip and a heart defect repair procedure or the repair procedure alone.